이 에피소드에 관해
Gout is often treated solely as a lifestyle problem. James Mackay calls that a myth.
In this episode of Power to the Patients, host Brandon Li sits down with James, CEO and co-founder of Crystalys Therapeutics, to unpack why gout has been misunderstood, under-prioritized, and under-innovated for decades. They also explore how biotech teams learn from setbacks, choose the right assets, design trials around patient reality, and return to an overlooked disease when the work is not finished.
What You’ll Learn:
- Why the “gout is caused by diet” narrative has done real damage to patient care
- How poor uric acid excretion drives the majority of gout cases
- What James Mackay learned from leading the Zurampic program through Phase 3 and approval
- Why renal toxicity became such an important lesson in URAT1 inhibitor development
- How Dotinurad’s smoother 12- to 14-hour profile changes the safety conversation
- Why Crystalys is positioning Dotinurad for patients who are not controlled on first-line therapies
- What it takes to run multiple clinical programs with a small, experienced biotech team
About James:
James Mackay is the CEO and co-founder of Crystalys Therapeutics, a clinical-stage biopharmaceutical company focused on transforming treatment options for people living with gout. Before Crystalys, James spent 30 years at AstraZeneca, where he worked across life sciences and business development before moving into biotech leadership. He previously led Ardea Biosciences after AstraZeneca acquired the company, taking Zurampic through Phase 3 development, regulatory submission, and approval. Today, James is applying those lessons to Dotinurad, Crystalys Therapeutics’ lead candidate and a next-generation oral URAT1 inhibitor being developed for patients with gout who remain uncontrolled on existing therapies.
Episode Resources:
- James Mackay on LinkedIn: http://linkedin.com/in/james-m-mackay
- Crystalys Therapeutics Website: https://crystalystx.com/
- Brandon Li on LinkedIn: https://www.linkedin.com/in/brandonhli/
- With Power Website: https://www.withpower.com/
- Power on LinkedIn https://www.linkedin.com/company/withpower/
영어
미국
이 에피소드 내
전사 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
이 팟캐스트의 다른 에피소드
Psychiatric drug development may be overcomplicating progress while overlooking effective treatments. Brandon Li speaks with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, about why clinical outcomes should matter more than novel mechanisms.
Jacobsen argues that the field’s fix…
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a systems…
In this episode of Power to the Patients, host Brandon Li speaks with Sonia Prashar, Founder and CEO of AIM Trials, about the future of psychiatry research and why patient-centric innovation is no longer optional. Drawing on more than 18 years of clinical research experience across multiple therape…
In this episode of Power to the Patients, Brandon Li speaks with Dr. Lara Shirikjian, board-certified psychiatrist and Medical Director at CenExel, about what it truly takes to build effective, ethical, and scalable psychiatric research programs.
Drawing on over 20 years of clinical and research ex…
What if the most effective way to treat some of the most devastating brain disorders isn’t by targeting symptoms in isolation, but by repairing the brain’s most fundamental unit of communication itself?
In this episode of Power to the Patients, host Brandon Li sits down with Dr. Craig Erickson, Res…
면책 조항: 이 페이지에 포함된 팟캐스트와 작품은 Brandon Li에서 가져온 것입니다. 이 팟캐스트는 소유자의 재산이며 Listen Notes, Inc.와 제휴하거나 보증하지 않습니다.
